2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Advanced Breast Cancer
2
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
ESR1 Gene Mutation
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Patients
1
Brain Neoplasms
1
Brain Diseases
1
Advanced ER+, HER2-Negative Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Cyclophosphamide
31
Trastuzumab
30
Paclitaxel
28
Docetaxel
22
Taxes
18
Doxorubicin
18
Radiotherapy
15
Lapatinib
15
Capecitabine
14
Bevacizumab
13
Tamoxifen
12
Carboplatin
11
Immunohistochemistry
9
Filgrastim
9
sargramostim
8
Granulocyte-Macrophage Colony-Stimulating Factor
8
Chemotherapy, Adjuvant
8
Biopsy
8
exemestane
7
Vorinostat
7
Magnetic Resonance Spectroscopy
7
Letrozole
7
Immunoenzyme Techniques
7
Gemcitabine
7
Anastrozole
7
Albumin-Bound Paclitaxel
7
pegfilgrastim
6
Neoadjuvant Therapy
6
Goserelin
6
Fluorodeoxyglucose F18
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms, Male
×
elacestrant
×
Clear all
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled